NO DOSAGE ADJUSTMENTS
NO DOSAGE ADJUSTMENTS ARE NECESSARY WITH ZYVOX
ZYVOX offers a demonstrated safety profile in a broad range of patients.
ZYVOX is readily distributed to well-perfused tissues.
* The plasma protein binding is 31% and concentration-independent
* Metabolism is not dependent on any single organ system
—Both active drug and metabolites are excreted by multiple routes
* ZYVOX is not detectably metabolized by the cytochrome P450 enzyme system, so interactions between ZYVOX and other medications metabolized by this system are unlikely
Peripheral and optic neuropathy have been reported in patients treated with ZYVOX, primarily those patients treated for longer than the maximum recommended duration of 28 days. In cases of optic neuropathy that progressed to loss of vision, patients were treated for extended periods beyond the maximum recommended duration. Visual blurring has been reported in some patients treated with ZYVOX for less than 28 days.
If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmic evaluation is recommended. Visual function should be monitored in all patients taking ZYVOX for extended periods (3 months) and in all patients reporting new visual symptoms regardless of length of therapy with ZYVOX. If peripheral or optic neuropathy occurs, the continued use of ZYVOX in these patients should be weighed against the potential risks.
ZYVOX has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.
ZYVOX offers a demonstrated safety profile in a broad range of patients.
ZYVOX is readily distributed to well-perfused tissues.
* The plasma protein binding is 31% and concentration-independent
* Metabolism is not dependent on any single organ system
—Both active drug and metabolites are excreted by multiple routes
* ZYVOX is not detectably metabolized by the cytochrome P450 enzyme system, so interactions between ZYVOX and other medications metabolized by this system are unlikely
Peripheral and optic neuropathy have been reported in patients treated with ZYVOX, primarily those patients treated for longer than the maximum recommended duration of 28 days. In cases of optic neuropathy that progressed to loss of vision, patients were treated for extended periods beyond the maximum recommended duration. Visual blurring has been reported in some patients treated with ZYVOX for less than 28 days.
If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmic evaluation is recommended. Visual function should be monitored in all patients taking ZYVOX for extended periods (3 months) and in all patients reporting new visual symptoms regardless of length of therapy with ZYVOX. If peripheral or optic neuropathy occurs, the continued use of ZYVOX in these patients should be weighed against the potential risks.
ZYVOX has not been studied in patients with uncontrolled hypertension, pheochromocytoma, carcinoid syndrome, or untreated hyperthyroidism.